Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 13/20 | 0.43 |
| ▸ | FNTB | P49356 | 13/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | BRS3 | P32247 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6976616 | 0.75 | FNTA (0.52) | FNTAFNTBPGGT1B | |
| SCHEMBL7483971 | 0.75 | FNTA (0.47) | FNTAFNTBCYP19A1PGGT1B | |
| Hydrochloric Acid SCHEMBL7482278 | 0.75 | FNTA (0.47) | FNTAFNTBCYP19A1PGGT1B | |
| SCHEMBL6610055 | 0.74 | ADRA2A (0.38) | FNTAFNTBCPA1ADRA2AADRA2B | |
| SCHEMBL6983089 | 0.74 | FNTA (0.41) | FNTAFNTBPGGT1B | |
| SCHEMBL6599134 | 0.73 | FNTA (0.37) | FNTAFNTBADRA2AADRA2BADRA2C | |
| SCHEMBL6972971 | 0.72 | FNTA (0.51) | FNTAFNTBPGGT1B | |
| SCHEMBL6977268 | 0.72 | FNTA (0.59) | FNTAFNTBPGGT1B | |
| SCHEMBL6607577 | 0.71 | FNTA (0.37) | FNTAFNTBADRA2AADRA2BADRA2C | |
| SCHEMBL4955195 | 0.71 | FNTA (0.60) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | disclosed |
| US-6518429-B2 | Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus | LG CHEMICAL, LTD. (KR) | 2003-02-11 | — | — | US | disclosed |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | LG CHEMICAL LTD. | 2002-09-26 | — | — | US | disclosed |
| US-6268363-B1 | ANTITUMOR | LG CHEMICAL LTD. (KR) | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | FNTA, FNTB, FDPS | FNTA 1/4885FNTB 2/4885CYP19A1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.